jueves, 6 de noviembre de 2014

Novartis...enfrenta la LEY: Ahora India

Fué en China:

CHINA: "Zorro" ataca Alcon...de Novartis.

También en Japón:

JAPON: Novartis allanada. Por qué...?

Ahora...en India

Drug major Novartis has been slapped with a Rs 300-crore penalty by drug regulator NPPA for overcharging consumers on sale of Voveran, its best-selling painkiller medicine. 

 The Swiss drugmaker, which did not confirm the quantum of the total penalty by the the National Pharmaceutical Pricing Authority (NPPA), said the notice is "erroneous and entirely misconceived". 

"Novartis has received a notice from NPPA and will duly respond to the same. Novartis believes the show cause notice to be erroneous and entirely misconceived and Novartis will challenge both the basis of the demand as well as the entire quantum of the demand," Novartis India Ltd today said in a filing to the BSE. Novartis had already filed a Writ Petition (prior to issue of the SCN) before the Hon'ble Delhi High Court and the matter is sub-judice, it added. 

 According to industry sources, the company has been slapped a notice of around Rs 300 crore by NPPA for overcharging consumers on sale of Voveran. Novartis' analgesic brand, Voveran, is based on diclofenac, a component that is under the government's direct price control.(Más)
Publicar un comentario